223 related articles for article (PubMed ID: 27623122)
1. [Interest of scopolamine as a treatment of major depressive disorder].
Rigal A; Mouchabac S; Peretti CS
Encephale; 2016 Dec; 42(6):568-573. PubMed ID: 27623122
[TBL] [Abstract][Full Text] [Related]
2. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
Furey ML; Drevets WC
Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
[TBL] [Abstract][Full Text] [Related]
3. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
Chen JCC; Sumner RL; Krishnamurthy Naga V; Hoeh N; Ayeni HA; Singh V; Sundram F; Campbell D; Muthukumaraswamy S
Trials; 2020 Feb; 21(1):157. PubMed ID: 32041658
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
[TBL] [Abstract][Full Text] [Related]
5. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study.
Khajavi D; Farokhnia M; Modabbernia A; Ashrafi M; Abbasi SH; Tabrizi M; Akhondzadeh S
J Clin Psychiatry; 2012 Nov; 73(11):1428-33. PubMed ID: 23146150
[TBL] [Abstract][Full Text] [Related]
6. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial.
Drevets WC; Furey ML
Biol Psychiatry; 2010 Mar; 67(5):432-8. PubMed ID: 20074703
[TBL] [Abstract][Full Text] [Related]
7. Scopolamine as an antidepressant: a systematic review.
Jaffe RJ; Novakovic V; Peselow ED
Clin Neuropharmacol; 2013; 36(1):24-6. PubMed ID: 23334071
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant treatment history as a predictor of response to scopolamine: clinical implications.
Ellis JS; Zarate CA; Luckenbaugh DA; Furey ML
J Affect Disord; 2014 Jun; 162():39-42. PubMed ID: 24767003
[TBL] [Abstract][Full Text] [Related]
9. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
[TBL] [Abstract][Full Text] [Related]
10. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.
Guo W; Machado-Vieira R; Mathew S; Murrough JW; Charney DS; Grunebaum M; Oquendo MA; Kadriu B; Akula N; Henter I; Yuan P; Merikangas K; Drevets W; Furey M; Mann JJ; McMahon FJ; Zarate CA; Shugart YY
Transl Psychiatry; 2018 Dec; 8(1):280. PubMed ID: 30552317
[TBL] [Abstract][Full Text] [Related]
11. Scopolamine produces larger antidepressant and antianxiety effects in women than in men.
Furey ML; Khanna A; Hoffman EM; Drevets WC
Neuropsychopharmacology; 2010 Nov; 35(12):2479-88. PubMed ID: 20736989
[TBL] [Abstract][Full Text] [Related]
12. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial.
McIntyre RS; Cucchiaro J; Pikalov A; Kroger H; Loebel A
J Clin Psychiatry; 2015 Apr; 76(4):398-405. PubMed ID: 25844756
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
[TBL] [Abstract][Full Text] [Related]
14. A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality.
Aaronson ST; Sears P; Ruvuna F; Bunker M; Conway CR; Dougherty DD; Reimherr FW; Schwartz TL; Zajecka JM
Am J Psychiatry; 2017 Jul; 174(7):640-648. PubMed ID: 28359201
[TBL] [Abstract][Full Text] [Related]
15. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
16. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
Akiskal HS; Benazzi F; Perugi G; Rihmer Z
J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
[TBL] [Abstract][Full Text] [Related]
17. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.
Aaronson ST; van der Vaart A; Miller T; LaPratt J; Swartz K; Shoultz A; Lauterbach M; Sackeim HA; Suppes T
JAMA Psychiatry; 2024 Jun; 81(6):555-562. PubMed ID: 38055270
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
[TBL] [Abstract][Full Text] [Related]
19. Scopolamine augmentation for depressive symptoms and cognitive functions in treatment-resistant depression: A case series.
Fang Y; Guo P; Lv L; Feng M; Wang H; Sun G; Wang S; Qian M; Chen H
Asian J Psychiatr; 2023 Apr; 82():103484. PubMed ID: 36736107
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
